Hunan Warrant Pharmaceutical (688799) Fundamentals 2026 — P/E 27.4x, Revenue Analysis | SniperIQ
Hunan Warrant Pharmaceutical (688799) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥6.3B, trading at ¥47.36 on the SHH. This SniperIQ fundamentals page covers Hunan Warrant Pharmaceutical's valuation (P/E 27.4x, P/B 3.1x), profitability (net margin 15.1%), revenue (¥1.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hunan Warrant Pharmaceutical's market cap?
Hunan Warrant Pharmaceutical (688799) has a market capitalization of approximately ¥6.3B, trading at ¥47.36 on the SHH. Market cap moves with the live share price.
What is Hunan Warrant Pharmaceutical's P/E ratio?
Hunan Warrant Pharmaceutical's trailing twelve-month P/E ratio is 27.4x, with a price-to-book (P/B) of 3.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hunan Warrant Pharmaceutical?
Hunan Warrant Pharmaceutical runs a net profit margin of 15.1%, a gross margin of 99.0%, and an operating margin of 15.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hunan Warrant Pharmaceutical generate?
Hunan Warrant Pharmaceutical reported revenue of ¥1.5B for fiscal year 2025, with net income of ¥241M and earnings per share (EPS) of 1.84. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hunan Warrant Pharmaceutical pay a dividend?
Hunan Warrant Pharmaceutical offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hunan Warrant Pharmaceutical financially healthy?
Hunan Warrant Pharmaceutical carries a debt-to-equity ratio of 0.32x and a current ratio of 2.83x, with a market beta of 0.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hunan Warrant Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hunan Warrant Pharmaceutical (688799) the key facts are: market cap ¥6.3B, P/E 27.4x, revenue ¥1.5B, 52-week range 40.51-66.88. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hunan Warrant Pharmaceutical's full fundamentals live
Get Hunan Warrant Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.